Pdx Model Establishment
Pdx Model Establishment - Related Videos
03:24
Establishing Experimental Metastases Mouse Model: Implanting GFP Expressing CRC Organoid Cells in PDX Model to Detect Micrometastases
0 Views •
2023
This video describes the protocol for generating metastases by the PDX derived CRC organoids labeled with GFP lentivirus into the spleen of an immunodeficient mouse. Cancer micrometastases colonizing other organs can be detected using a fluorescence microscope to assess the GFP expression.
04:49
Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
0 Views •
Cited by 9 •
2021
A method is described to create organoids using patient-derived xenografts (PDX) for in vitro screening, resulting in matched pairs of in vivo/in vitro models. PDX tumors were harvested/processed into small pieces mechanically or enzymatically, followed by the Clevers’ method to grow tumor organoids that were passaged, cryopreserved and characterized against the original PDX.
06:48
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
0 Views •
2025
This protocol describes in ovo xenografting of patient-derived B- and T-acute lymphoblastic leukemia (ALL) cells, which occurs 4 days following injection.
08:40
Establishment and Characterization of UTI and CAUTI in a Mouse Model
0 Views •
Cited by 51 •
2015
The ability to model urinary tract infections (UTI) is crucial in order to be able to understand bacterial pathogenesis and spawn the development of novel therapeutics. This work’s goal is to demonstrate mouse models of experimental UTI and catheter associated UTI that recapitulate and predict findings seen in humans.
03:19
Transduction to Label PDX Tumor Cells: Introducing Lentivirus Expressing Fluorescent Marker into the Tumor Cell In Vitro
0 Views •
2023
The following video describes a technique of transduction to label (patient-derived xenografts) PDX tumor cells, which is used for introducing lentivirus expressing green-fluorescent protein and luciferase reporters into the tumor cell in vitro.
FAQs
Serial transplantation extends the model beyond the initial implantation by transferring established tumor material into additional host mice. This process is associated with monitoring continued engraftment and growth, helping researchers maintain a usable experimental system. It also supports repeated evaluation of tumor behavior and treatment response across studies once the model has been established.
PDX models can retain clinically relevant features such as tumor heterogeneity, histology, and aspects of treatment response. Preserving heterogeneity is important because a patient’s tumor may contain distinct cellular populations, while retained histology helps researchers examine tissue features in an experimental setting. Together, these characteristics make the models useful for studying tumor biology and therapy effects.
Because PDX hosts lack a fully functional human immune system, the models cannot represent every aspect of cancer biology or treatment response. This limitation is particularly relevant when an application depends on interactions involving the human immune system. Researchers therefore need to interpret findings within the model’s scope rather than treating every result as a complete representation of patient disease.
The workflow begins with collection of a fresh tumor specimen, followed by implantation of tumor fragments or cells into an immunodeficient animal. Researchers then monitor whether the tissue engrafts and how it grows. When an established model is available, serial transplantation can be used to continue the model and support subsequent cancer research experiments.
Once a tumor has engrafted and produced an established model, researchers can use it for preclinical evaluation of anticancer drugs. The same platform also supports testing combination therapies, allowing treatment responses to be examined in tumor material that may retain clinically relevant heterogeneity and histology. These studies provide experimental evidence before therapies are considered in broader settings.
PDX models may help inform personalized treatment strategies by preserving selected features of an individual patient’s tumor and allowing treatment responses to be studied experimentally. Their value is strongest when researchers connect model behavior with the original cancer’s characteristics. However, conclusions remain limited by the absence of a fully functional human immune system and should be interpreted accordingly.